Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial

Ideaya sees clear path to FDA as Servier-partnered eye cancer drug hits goal in phase 2/3 trial

  • April 13, 2026

A phase 2/3 trial of Ideaya Biosciences and Servier’s eye cancer candidate has hit its primary endpoint, teeing up a filing for accelerated FDA approval in the second half of the year.

Leave A Comment

Fields (*) Mark are Required